Insulin Sensitivity in Multiple Pathways Is Differently Affected During Zidovudine/Lamivudine-Containing Compared With NRTI-Sparing Combination Antiretroviral Therapy
暂无分享,去创建一个
P. Reiss | H. Yki-Jărvinen | H. Sauerwein | J. Sutinen | M. Ackermans | M. Serlie | S. Danner | M. V. van Agtmael | M. V. van Vonderen | R. M. Blümer | E. Hassink | Jussi Sutinen
[1] S. Weise,et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients , 2009, AIDS.
[2] S. Cole,et al. Antiretroviral Therapy Exposure and Insulin Resistance in the Women's Interagency HIV Study , 2008, Journal of acquired immune deficiency syndromes.
[3] P. Reiss,et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy , 2008, AIDS.
[4] S. Cole,et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study , 2007, AIDS.
[5] M. Noor,et al. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: Cellular mechanisms and clinical implications , 2007, Current HIV/AIDS reports.
[6] W. Frontera,et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. , 2007, American journal of physiology. Endocrinology and metabolism.
[7] J. Capeau,et al. Some HIV Antiretrovirals Increase Oxidative Stress and Alter Chemokine, Cytokine or Adiponectin Production in Human Adipocytes and Macrophages , 2007, Antiviral therapy.
[8] K. Petersen,et al. Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction , 2006, Diabetes.
[9] R. Considine,et al. Insulin sensitivity is preserved despite disrupted endothelial function. , 2006, American journal of physiology. Endocrinology and metabolism.
[10] R. Parker,et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically , 2006, AIDS.
[11] M. Schambelan,et al. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] S. Weise,et al. Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. , 2006, American journal of physiology. Endocrinology and metabolism.
[13] Francesc Villarroya,et al. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. , 2005, Trends in pharmacological sciences.
[14] P. Hruz,et al. A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity* , 2004, Journal of Biological Chemistry.
[15] Madhu N. Rao,et al. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism , 2004, Current infectious disease reports.
[16] R. Parker,et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults , 2004, AIDS.
[17] M. Schambelan,et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. , 2004, Journal of acquired immune deficiency syndromes.
[18] M. Schambelan,et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men , 2004, AIDS.
[19] H. Pownall,et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of ‘systemic steatosis’ , 2004, Current opinion in lipidology.
[20] C. Pond,et al. Site-specific differences in the action of NRTI drugs on adipose tissue incubated in vitro with lymphoid cells, and their interaction with dietary lipids. , 2003, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.
[21] S. Welle,et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. , 2003, Diabetes.
[22] C. Mantzoros,et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. , 2003, The Journal of clinical endocrinology and metabolism.
[23] P. Scherer,et al. Adiponectin and Leptin Levels in HIV‐Infected Subjects With Insulin Resistance and Body Fat Redistribution , 2002, Journal of acquired immune deficiency syndromes.
[24] F. van Leth,et al. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. , 2002, Journal of Clinical Endocrinology and Metabolism.
[25] M. Schambelan,et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.
[26] P. Reiss,et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways , 2001, AIDS.
[27] P. Scherer,et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.
[28] I. Harman-boehm,et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. , 2001, Diabetes.
[29] E. Furfine,et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. , 2000, Antiviral research.
[30] P. Hruz,et al. The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy* , 2000, The Journal of Biological Chemistry.
[31] J. M. Aerts,et al. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. , 2007, The Journal of clinical endocrinology and metabolism.